Acumen develops targeted therapies for the safe and effective treatment of Alzheimer’s and related neurodegenerative diseases. The company's founders pioneered discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field.
Our lead drug candidate, ACU193, is a humanized, affinity-matured, IgG2m4 subclass monoclonal antibody (mAb) that has high selectivity for toxic Aβo over Aβ monomers and amyloid plaques.
ACU193 is expected to provide a meaningful benefit for Early Alzheimer's patients without safety-related ARIA-E because it blocks the cytotoxic effects of the Aβo without directly targeting amyloid plaques.
ACU193 will enter Phase 1 clinical testing in early 2021.
Our lead drug candidate, ACU193, is a humanized, affinity-matured, IgG2m4 subclass monoclonal antibody (mAb) that has high selectivity for toxic Aβo over Aβ monomers and amyloid plaques.
ACU193 is expected to provide a meaningful benefit for Early Alzheimer's patients without safety-related ARIA-E because it blocks the cytotoxic effects of the Aβo without directly targeting amyloid plaques.
ACU193 will enter Phase 1 clinical testing in early 2021.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Virginia
Company HQ Country:
United States
Year Founded:
1996
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
ACU193
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
